10-Q: Viridian Secures $70M Upfront, Advances TED & FcRn Programs

Viridian Therapeutics reports a $70 million license revenue, significant progress in its veligrotug and VRDN-003 TED programs, and expanded FcRn inhibitor pipeline, alongside increased operating losses.

Summary

• Net loss for the nine months ended September 30, 2025, was $222.2 million, an increase from $190.2 million in the same period of 2024.
• The accumulated deficit as of September 30, 2025, reached $1,218.1 million.
• Cash, cash equivalents, and short-term investments totaled $490.9 million as of September 30, 2025.
• Secured a $70.0 million upfront payment from Kissei Pharmaceutical Co., Ltd. for an exclusive license to develop and commercialize veligrotug and VRDN-003 in Japan, with potential for up to $315.0 million in additional milestone payments and tiered royalties.
• Veligrotug, a treatment for Thyroid Eye Disease (TED), received Breakthrough Therapy designation from the U.S. FDA in May 2025 and a Biologics License Application (BLA) was submitted to the FDA in October 2025.
• Anticipates submitting a Marketing Authorization Application (MAA) for veligrotug to the European Medicines Agency (EMA) in the first quarter of 2026.
• Phase 3 THRIVE and THRIVE-2 trials for veligrotug in active and chronic TED met all primary and secondary endpoints with high statistical significance and a generally well-tolerated safety profile.
• The STRIVE safety trial for veligrotug completed enrollment with 231 patients in January 2025, exceeding its target.
• VRDN-003, a subcutaneous TED candidate, showed a prolonged half-life of 40 to 50 days in Phase 1 studies.
• Pivotal Phase 3 REVEAL-1 and REVEAL-2 trials for VRDN-003 in active and chronic TED completed enrollment in September 2025, exceeding targets with 132 and 204 patients, respectively.
• A VRDN-003 safety study completed enrollment in October 2025 with 321 patients, exceeding its target.
• Anticipates submitting a BLA for VRDN-003 for the treatment of TED by the end of 2026.
• The Investigational New Drug (IND) application for VRDN-006 (FcRn inhibitor) cleared in January 2025, with Phase 1 data showing IgG reductions consistent with the class and sparing albumin/LDL.
• Anticipates submitting an IND for VRDN-008 (FcRn inhibitor) by the end of 2025, with healthy volunteer data expected in 2026.
• Post-period, entered a Purchase and Sale Agreement with DRI Healthcare Acquisitions LP for U.S. revenue streams, receiving $55.0 million upfront and eligible for up to $245.0 million in additional milestone payments.
• Post-period, amended the Hercules Loan and Security Agreement, increasing the facility to $300.0 million (with an initial $50.0 million drawn) and extending maturity to October 2030.
• Post-period, completed an October 2025 Public Offering, raising $251.4 million gross proceeds, plus an additional $37.7 million from the over-allotment option exercise.
• Management believes existing cash, investments, and recent financing will fund operations to break even.
• Research and development expenses increased by $83.4 million to $249.7 million for the nine months ended September 30, 2025, primarily due to increased clinical trial and manufacturing costs for the TED portfolio.
• General and administrative expenses increased by $16.1 million to $61.6 million for the nine months ended September 30, 2025, driven by increased headcount and market research for veligrotug commercialization.

Sentiment

Score: 8

Explanation: The company has achieved critical clinical and regulatory milestones for its lead programs, including BLA submission for veligrotug and completion of pivotal trial enrollment for VRDN-003. Multiple significant financing events have substantially bolstered its financial position, providing a clear path to fund operations to break even. While losses are increasing, this is expected for a company advancing multiple late-stage assets.

Positives

• Secured a $70.0 million upfront payment from Kissei Pharmaceutical Co., Ltd. for exclusive Japan rights to veligrotug and VRDN-003, with eligibility for up to an additional $315.0 million in milestone payments and tiered royalties.
• Veligrotug received Breakthrough Therapy designation from the U.S. FDA in May 2025, potentially supporting eligibility for Priority Review.
• Submitted a Biologics License Application (BLA) for veligrotug to the FDA in October 2025, a major regulatory milestone.
• Anticipates submitting a Marketing Authorization Application (MAA) for veligrotug to the European Medicines Agency (EMA) in Q1 2026, expanding global regulatory efforts.
• Phase 3 THRIVE and THRIVE-2 trials for veligrotug in active and chronic TED met all primary and secondary endpoints with high statistical significance and a generally well-tolerated safety profile.
• Veligrotug demonstrated positive durability at 52 weeks in the THRIVE study, with 70% of proptosis responders at week 15 maintaining their response.
• The STRIVE safety trial for veligrotug completed enrollment with 231 patients in January 2025, exceeding its target enrollment.
• VRDN-003 Phase 1 study in healthy volunteers showed a prolonged half-life of 40 to 50 days, four to five times that of veligrotug, suggesting potential for less frequent dosing.
• Pivotal Phase 3 REVEAL-1 and REVEAL-2 trials for VRDN-003 in active and chronic TED completed enrollment in September 2025, both exceeding their target enrollments due to demand.
• The VRDN-003 safety study completed enrollment in October 2025 with 321 patients, exceeding its target enrollment.
• The Investigational New Drug (IND) application for VRDN-006 cleared in January 2025, and Phase 1 data showed IgG reductions consistent with the FcRn inhibitor class while sparing albumin and LDL.
• Secured up to $300.0 million in consideration from DRI Healthcare Acquisitions LP for U.S. revenue streams, including a $55.0 million upfront payment.
• Amended the Hercules Loan and Security Agreement, increasing the facility to $300.0 million and extending maturity to October 2030, with an initial $50.0 million drawn.
• Successfully completed an October 2025 Public Offering, raising $251.4 million gross proceeds, plus an additional $37.7 million from the over-allotment option exercise, significantly bolstering capital resources.
• Management believes existing cash, investments, and recent financing will fund operations to break even, indicating improved financial runway.

Negatives

• Incurred a net loss of $222.2 million for the nine months ended September 30, 2025, an increase from $190.2 million in the same period of 2024.
• The accumulated deficit reached $1,218.1 million as of September 30, 2025, reflecting substantial historical losses.
• Cash and cash equivalents decreased from $99.6 million at December 31, 2024, to $169.6 million at September 30, 2025, while short-term investments decreased from $618.0 million to $321.3 million, leading to a reduction in total current assets from $738.5 million to $571.9 million (pre-subsequent events).
• Research and development expenses increased significantly by $83.4 million to $249.7 million for the nine months ended September 30, 2025, indicating high burn rate.
• General and administrative expenses increased by $16.1 million to $61.6 million for the nine months ended September 30, 2025, contributing to increased operating losses.
• Interest income decreased from $23.1 million in 2024 to $19.6 million in 2025 for the nine-month period.
• The company has no products approved for commercial sale and has not generated any revenue from product sales to date, relying heavily on financing activities.

Risks

• Inability to secure additional capital when needed, potentially forcing delays, reductions, or elimination of research, product development, or commercialization efforts.
• Continued significant losses for the foreseeable future, with an accumulated deficit of $1,218.1 million as of September 30, 2025.
• Clinical trials are costly, time-consuming, and inherently risky, with no guarantee of demonstrating safety and efficacy to regulatory authorities' satisfaction.
• Regulatory approval processes are lengthy, unpredictable, and may be delayed by factors beyond control, including government shutdowns.
• Product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit commercial viability, or result in negative consequences post-marketing.
• Heavy dependence on the success of product candidates in clinical development, with no assurance of generating sufficient data for regulatory approval.
• Product development is a lengthy and expensive process with uncertain outcomes, and early-stage results may not predict future clinical trial results.
• Reliance on third parties (CROs, CDMOs) for nonclinical development, clinical trials, and manufacturing; failure of these parties could harm business.
• Inability to obtain or maintain intellectual property rights (patents, trade secrets) could impair competitive effectiveness.
• Inability to establish commercial manufacturing, sales, and marketing capabilities or secure third-party agreements could prevent revenue generation.
• Substantial competition from major pharmaceutical and biotechnology companies, potentially developing products faster or more successfully.
• Future success depends on attracting, retaining, and motivating qualified personnel; loss of key personnel or failure to recruit could impair product development.
• Uncertainty regarding the timing or availability of additional funds under the DRI Purchase and Sale Agreement or Hercules Second Amendment, as milestones are conditional.
• Potential for dilution to stockholders from future capital raises through equity or convertible debt.
• Business disruptions (e.g., acts of war, natural disasters, supply chain weaknesses, geopolitical instability) could harm revenue and financial condition.
• Preliminary clinical data is subject to audit and verification, and final results may differ materially from preliminary reports.
• Risk of using financial and human resources on less profitable programs, foregoing more successful opportunities.
• Potential product liability claims from the use or misuse of approved products or product candidates.
• Inability to obtain or maintain adequate pricing, reimbursement, or insurance coverage for products, if approved.
• Challenges in developing internal commercialization capabilities, potentially impacting sales.
• Risks associated with reliance on third-party manufacturers, especially single-sourced ones and those in China (e.g., WuXi Biologics), due to geopolitical tensions, trade restrictions, and potential legislation like the BIOSECURE Act.
• Inability to realize potential benefits from collaborations.
• Insufficient patent term protections for product candidates.
• Changes in patent laws could diminish patent value.
• Third-party claims of intellectual property infringement.
• Dependence on intellectual property licensed from third parties, with risks of losing license rights.
• Involvement in lawsuits or post-grant review proceedings to defend patents.
• Claims that employees or contractors wrongfully used or disclosed confidential information of third parties.
• Claims challenging inventorship of patents.
• Inability to protect intellectual property rights globally.
• Product candidates regulated as biologics may face competition from biosimilar products.
• Uncertainty in obtaining orphan drug designation or maintaining its benefits.
• Fast Track, Breakthrough Therapy, or Priority Review designations may not lead to faster development or approval.
• Risks associated with seeking accelerated approval, including confirmatory trials and potential withdrawal of approval.
• Impact of healthcare legislative reform measures (e.g., IRA) on business, costs, and pricing.
• Exposure to foreign, federal, and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws.
• Failure to comply with environmental, health, and safety laws.
• Non-compliance with privacy or data security laws (e.g., GDPR, CCPA).
• Adverse impacts from the use of artificial intelligence (AI) or other emerging technologies.
• Covenants in the Hercules Loan and Security Agreement could restrict operations or force early repayment.
• Failure in information technology and storage systems, or those of third parties.
• Limitations on the ability to use net operating loss carryforwards and other tax attributes.
• Changes in tax laws or regulations.
• Volatility in the market price of common stock.
• Risks related to litigation and other legal proceedings.
• Costs and demands from complying with public company laws and regulations.
• Impact of equity research analysts' reports on stock price.
• Failure to maintain proper and effective internal controls.

Future Outlook

Anticipates submitting an Investigational New Drug Application (IND) for VRDN-008 by the end of 2025, with healthy volunteer data expected in 2026. The company also expects to submit a Marketing Authorization Application (MAA) for veligrotug to the EMA in Q1 2026. Topline data for VRDN-003's REVEAL-1 trial is expected in Q1 2026, and for REVEAL-2 in Q2 2026, with a Biologics License Application (BLA) for VRDN-003 for TED anticipated by the end of 2026. Research and development expenses are expected to remain consistent. Management believes that existing cash, cash equivalents, short-term investments, the Kissei upfront payment, the DRI upfront payment, potential near-term DRI milestones, the Hercules Second Amendment draw, and anticipated veligrotug and VRDN-003 sales (if approved on anticipated timelines) will be sufficient to fund planned operations to break even.

Management Comments

• We are a biopharmaceutical company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases.
• We believe that first-generation medicines rarely represent optimal solutions, especially in rare disease areas, and that there is potential to develop differentiated, best-in-class medicines that could lead to improved patient outcomes, reduced side effects, improved quality of life, expanded market access, and augmented market competition.
• Our goal is to identify and evaluate product concepts leveraging clinically validated molecular targets using established therapeutic modalities.
• We believe this strategy reduces the risks associated with discovering and developing novel therapeutics.
• We believe VRDN-003 has the potential to be the best-in-class subcutaneous anti-IGF-1R product candidate by preserving the efficacy of anti-IGF-1Rs in TED, improving safety and maximizing convenience for patients.
• We expect our research and development expenses to remain consistent as we continue to advance our clinical and nonclinical programs.
• We expect that our existing cash, cash equivalents and short-term investments as of September 30, 2025 of $490.9 million will enable the Company to fund its planned operations for at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements.
• Based on our current business plans, we believe that the $272.4 million in net proceeds from the October 2025 Public Offering, together with our existing current cash, cash equivalents, short-term investments, the $70.0 million upfront payment receivable from Kissei, which was paid in the fourth quarter 2025, the $55.0 million upfront payment that we received in connection with our entry into the DRI Purchase and Sale Agreement and the $115.0 million in potential near-term milestones anticipated under the DRI Purchase and Sale Agreement, the $30.0 million received by the Company from the Hercules Second Amendment, and anticipated revenue from veligrotug and VRDN-003 sales, if each is approved on our anticipated timelines, will be sufficient to fund our planned operations to break even where our anticipated revenues fund our anticipated operating expenses.

Industry Context

Viridian operates in the highly competitive biopharmaceutical industry, focusing on rare autoimmune diseases like Thyroid Eye Disease (TED) and developing FcRn inhibitors for a broad array of autoimmune diseases. The company positions its product candidates (veligrotug, VRDN-003) as 'fast-follower' therapeutics aiming to improve upon existing therapies like Tepezza (teprotumumab) by Amgen, which is the only FDA-approved medicine for TED. Improvements are sought in dosing schedule, route of administration, and safety profile. The FcRn inhibitor space is also competitive, with companies like Argenx, UCB S.A., Johnson & Johnson, and Immunovant, Inc. having marketed or in-development therapeutics. Viridian aims to differentiate VRDN-006 and VRDN-008 by addressing limitations of current agents, such as incomplete IgG suppression, safety, and dosing inconvenience. The industry faces global macroeconomic uncertainties, including increased U.S. trade tariffs, supply chain weaknesses, and geopolitical instability, which could impact operations and costs.

Comparison to Industry Standards

• Veligrotug is compared to Tepezza (teprotumumab) by Amgen Inc., the only FDA-approved medicine for TED, with Viridian's five-dose IV regimen featuring fewer infusions and a shorter time per infusion.
• In vitro nonclinical data showed veligrotug as a potentially differentiated full antagonist of IGF-1R, compared to teprotumumab's incomplete antagonism of IGF-1R.
• VRDN-003 is designed for convenient, low-volume, infrequently-dosed subcutaneous auto-injector injections, aiming to be a best-in-class subcutaneous anti-IGF-1R product candidate by preserving efficacy, improving safety, and maximizing convenience for patients.
• VRDN-003's prolonged half-life of 40 to 50 days is four to five times that of veligrotug, suggesting a significant dosing advantage.
• VRDN-006 demonstrated comparable potency and IgG reductions to efgartigimod, a current standard of care in FcRn inhibition, as well as a similar safety profile in non-human primate (NHP) studies.
• VRDN-006 showed specificity for blocking FcRn-IgG interactions while not showing decreases in albumin or increases in low-density lipoprotein (LDL) levels, which are known potential side effects associated with certain full-length anti-FcRn monoclonal antibodies.
• VRDN-008 demonstrated three times the half-life of efgartigimod and a deeper and more sustained IgG reduction with peak IgG reductions that were 20% deeper than efgartigimod in NHP studies.
• IgG levels returned to baseline 35 days after VRDN-008 dosing, more than twice as long as efgartigimod, which returned to baseline 14 days after dosing, indicating superior durability.

Corporate Governance

Legal Proceedings

• Currently not a party to any legal proceedings that are believed to have a material adverse effect on the business, financial condition, or results of operations.

Related Party Transactions

• License agreement, letter agreements, and supply agreement (Zenas Agreements) with Zenas BioPharma are considered related party transactions due to Fairmount Funds Management LLC's beneficial ownership in Viridian and a Fairmount member's seat on Zenas BioPharma's board.
• Side Agreement and Material Transfer Agreement (MTA) with Zai Lab are considered related party transactions because Zenas BioPharma determined Zai Lab is its related party, given Zenas BioPharma's CEO and chairman also serves as a member of Zai Lab's board of directors.
• Antibody and discovery option agreement and license agreement (Paragon Agreements) with Paragon Therapeutics, Inc. are considered related party transactions due to Fairmount Funds Management LLC's beneficial ownership in both Viridian and Paragon, and its influence on Paragon's board and executive appointments.

Stakeholder Impact

• Shareholders face potential dilution from recent and future equity raises but also stand to benefit from significant value creation if product candidates achieve regulatory approval and commercial success.
• Employees are impacted by increased headcount to support R&D and commercialization efforts, with equity awards serving as a key retention tool in a competitive talent market.
• Patients (potential customers) may benefit from new, differentiated, and 'best-in-class' treatment options for serious and rare autoimmune diseases like TED, with potential for improved efficacy, safety, and convenience (e.g., subcutaneous auto-injector).
• Suppliers and partners, including third-party CROs and CDMOs, continue to be critical, facing risks related to supply chain, geopolitical tensions, and regulatory compliance, while new collaborations (Kissei, DRI) expand partnership opportunities.
• Creditors, such as Hercules Capital, Inc., have extended their loan facility and maturity, indicating continued confidence, though loan covenants remain in effect.

Next Steps

• Submit Marketing Authorization Application (MAA) for veligrotug to the EMA in Q1 2026.
• Anticipate topline data for REVEAL-1 (VRDN-003) in Q1 2026.
• Anticipate topline data for REVEAL-2 (VRDN-003) in Q2 2026.
• Anticipate submitting an Investigational New Drug (IND) application for VRDN-008 by the end of 2025.
• Expect healthy volunteer data for VRDN-008 in 2026.
• Anticipate submitting a Biologics License Application (BLA) for VRDN-003 for the treatment of TED by the end of 2026.
• Continue to advance clinical and nonclinical programs.
• Prepare for potential commercialization of veligrotug and VRDN-003.
• Evaluate options and take steps to establish development and/or manufacture of product candidates at new manufacturers to mitigate single-source reliance.

Key Dates

Recommendation

Viridian Therapeutics has demonstrated strong progress in its clinical pipeline, particularly with veligrotug's BLA submission and Breakthrough Therapy designation, and VRDN-003's pivotal trial enrollment completion. The recent capital raises significantly de-risk the company's financial runway, addressing immediate funding concerns and supporting future commercialization efforts. However, the company remains pre-revenue with substantial accumulated losses, and future success hinges on regulatory approvals and market acceptance, which are inherently uncertain. The stock has likely already reacted to the positive clinical and financing news. A 'Hold' recommendation reflects the positive momentum and improved financial stability, balanced against the inherent risks of clinical-stage biopharmaceutical development and the need for successful commercialization.

Keywords

Biopharmaceutical, Thyroid Eye Disease, TED, FcRn Inhibitor, Veligrotug, VRDN-003, VRDN-006, VRDN-008, Clinical Trials, Regulatory Approval, Drug Development, Autoimmune Disease, Breakthrough Therapy, Capital Raise, Biotechnology, Pharmaceutical, SEC Filing, 10-Q